BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perales C, Beach NM, Sheldon J, Domingo E. Molecular basis of interferon resistance in hepatitis C virus. Current Opinion in Virology 2014;8:38-44. [DOI: 10.1016/j.coviro.2014.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Mostafa AM, Saafan HA, Al-Tawashi AS, Kasem MH, Alaa AM, Eltobgy MM, Moubarak AS, Gharib MM, Awwad MA, Omar HM, El-Derany MO. Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients. Virus Res 2021;292:198226. [PMID: 33171166 DOI: 10.1016/j.virusres.2020.198226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Domingo E. Quasispecies dynamics in disease prevention and control. Virus as Populations 2020. [DOI: 10.1016/b978-0-12-816331-3.00008-8] [Reference Citation Analysis]
3 Domingo E. Trends in antiviral strategies. Virus as Populations 2020. [DOI: 10.1016/b978-0-12-816331-3.00009-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sánchez-Campos S, Domínguez-Huerta G, Díaz-Martínez L, Tomás DM, Navas-Castillo J, Moriones E, Grande-Pérez A. Differential Shape of Geminivirus Mutant Spectra Across Cultivated and Wild Hosts With Invariant Viral Consensus Sequences. Front Plant Sci 2018;9:932. [PMID: 30013589 DOI: 10.3389/fpls.2018.00932] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
5 Fukuhara T, Yamamoto S, Ono C, Nakamura S, Motooka D, Mori H, Kurihara T, Sato A, Tamura T, Motomura T, Okamoto T, Imamura M, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y, Chayama K, Matsuura Y. Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity. Sci Rep 2017;7:45228. [PMID: 28327559 DOI: 10.1038/srep45228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Perales C, Ortega-prieto AM, Beach NM, Sheldon J, Menéndez-arias L, Domingo E. Quasispecies and Drug Resistance. Handbook of Antimicrobial Resistance 2017. [DOI: 10.1007/978-1-4939-0694-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
8 Perales C, Domingo E. Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold. Curr Top Microbiol Immunol 2016;392:323-39. [PMID: 26294225 DOI: 10.1007/82_2015_459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
9 Cuypers L, Snoeck J, Kerremans L, Libin P, Crabbé R, Van Dooren S, Vuagniaux G, Vandamme AM. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Infect Genet Evol 2016;44:169-81. [PMID: 27374748 DOI: 10.1016/j.meegid.2016.06.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Domingo E. Quasispecies Dynamics in Disease Prevention and Control. Virus as Populations 2016. [DOI: 10.1016/b978-0-12-800837-9.00008-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Domingo E. Interaction of Virus Populations with Their Hosts. Virus as Populations 2016. [DOI: 10.1016/b978-0-12-800837-9.00004-6] [Reference Citation Analysis]
12 Domingo E. Trends in Antiviral Strategies. Virus as Populations 2016. [DOI: 10.1016/b978-0-12-800837-9.00009-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
14 Liu Y, Zou Z, Zhu B, Hu Z, Zeng P, Wu L. LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes. Hepat Mon 2015;15:e28473. [PMID: 26045710 DOI: 10.5812/hepatmon.15(5)2015.28473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
15 Rossi LM, Escobar-Gutierrez A, Rahal P. Advanced molecular surveillance of hepatitis C virus. Viruses 2015;7:1153-88. [PMID: 25781918 DOI: 10.3390/v7031153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
16 Menéndez-Arias L, Richman DD. Editorial overview: antivirals and resistance: advances and challenges ahead. Curr Opin Virol 2014;8:iv-vii. [PMID: 25155454 DOI: 10.1016/j.coviro.2014.08.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sheldon J, Beach NM, Moreno E, Gallego I, Piñeiro D, Martínez-Salas E, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol 2014;88:12098-111. [PMID: 25122776 DOI: 10.1128/JVI.01860-14] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
18 Perales C, Ortega-prieto AM, Beach NM, Sheldon J, Menéndez-arias L, Domingo E. Quasispecies and Drug Resistance. Handbook of Antimicrobial Resistance 2014. [DOI: 10.1007/978-1-4939-0667-3_1-1] [Reference Citation Analysis]